Znn3bq.jpeg
²é¿´: 1259  |  »Ø¸´: 3
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

ÒøÉþ

ľ³æ (ÖøÃûдÊÖ)

Ö²Îï²ËÄñ

[ÇóÖú] ¹ØÓÚRRAFµÄÓ¢ÎÄ·­Ò룬ÓÐЩ¼±£¬Âé·³°ïæ½âÊÍÏ£¬·Ç³£¸Ðл£¡

1.BRAF inhibitors drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling in oncogenic RAS revealing a paradigm of BRAF-mediated signaling that promotes tumour progression with clinical implications and highlighting the importance of understanding pathway signaling in clinical practice and of genotyping tumours prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects such as increased invasion¡£
ÕâÊÇÍêÕûµÄÒ»¾ä»°£¬ÓÐЩ³¤£¬Ö÷ÒªÏëÖªµÀRAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling £¬a paradigm of BRAF-mediated signalingÊÇʲôÒâ˼
2.panRAF inhibitors with anti SRC activity
°®ºÃÖ²Îµ«ÊÇÊÇÒ»Ö»²ËÄñ£¡
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÒøÉþ

ľ³æ (ÖøÃûдÊÖ)

Ö²Îï²ËÄñ

Çó´óÉñ°ïæ

[ ·¢×ÔСľ³æ¿Í»§¶Ë ]
°®ºÃÖ²Îµ«ÊÇÊÇÒ»Ö»²ËÄñ£¡
2Â¥2015-05-09 22:59:41
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

genhunter

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

BRAF inhibitors drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling in oncogenic RAS revealing a paradigm of BRAF-mediated signaling that promotes tumour progression with clinical implications and highlighting the importance of understanding pathway signaling in clinical practice and of genotyping tumours prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects such as increased invasion¡£
BRAF ÒÖÖÆ¼Á´ÙʹRAS-ÒÀÀµµÄBRAF½áºÏµ½CRAF, CRAFµÄ»î»¯£¬ÒÔ¼°Ö°© RASÐźŴ«µÝͨµÀÖеÄMEK-ERKÐźŴ«µÝ×÷ÓýÒʾÁËÒ»¸öÓÉ BRAF-½éµ¼µÄ£¬¸´ÔÓµÄÐźŴ«µÝ;¾¶£¬ÔÚ¾ßÓÐÁÙ´²Ñ§ÒâÒåµÄ´Ù½øÖ×Áö¶ñ»¯½ø³Ì(µÄ×÷ÓÃ), Í»³öÁËÁ˽â¸ÃÐźŴ«µÝ;¾¶ÔÚÁÙ´²Ó¦ÓÃÉϺÍÔÚʹÓÃBRFA-Ñ¡ÔñÐÔÒ©Îï֮ǰ¶ÔÖ×Áö×÷»ùÒò·ÖÀàµÄÖØÒªÐÔ£¬ÒÔ¼°¼ø±ðÄÄЩ»¼Õß¿ÉÄܶԴËÀàÒ©ÎïÓÐЧ£¬¶øÄÄЩ»á³öÏÖÔö¼ÓÀýÈçÖ×Áö×ªÒÆµÄ²»Á¼·´Ó¦¡£
Àë³É¹¦»¹²îÒ»µã
3Â¥2015-05-09 23:20:27
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ssssllllnnnn

ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)

Translator and Proofreader


¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
ÒøÉþ: ½ð±Ò+10, ·­ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, лл´óÉñµÄÄÍÐĽâ´ð£¬°ïÖúºÜ´ó 2015-05-10 12:40:36
ÍêÈ«Àí½âÕâ¾ä»°ÐèÒªÁ˽âRAS¡¢BRAF¡¢CRAFÒÔ¼°MEK-ERKÕâЩ»ù±¾µÄ¶«Î÷¼°ÆäÒâÒå¡£ÏÔÈ»Õâ²»ÊÇÒ»Á½¾ä»°¾ÍÄÜ˵µÄÇå³þµÄ¡£¼òµ¥Ëµ£º
1¡¢RasÊÇÒ»ÖÖ°©»ùÒò£¨oncogene£©£¬Æä±àÂë²úÎïÒÔÒ»ÖÖСGTPø£¨small GTPase£©£¬²ÎÓëÖØÒªµÄÐźŴ«µ¼¹ý³Ì£¨°üÀ¨ÄãµÄÄÚÈÝ£©£¬RasÊÇÒ»¸ö¼Ò×壬Óжà¸ö³ÉÓ°üÀ¨K-ras, H-ras, N-rasµÈ£»
2¡¢RAFÊÇÒ»ÀàË¿°±Ëá/ËÕ°±ËáÌØÒìÐÔµ°°×¼¤Ã¸£¨serine/threonine-specific protein kinases£©£¬¼ò³ÆÎªRaf¼¤Ã¸£¨Raf kinase£©£¬ÓÉÈý¸ö³ÉÔ±£¬·Ö±ðΪA-RAF, B-RAFºÍC-RAF£¬ÆäÖÐC-RAFÒ²³ÆÎªRaf-1£¬ÄãµÄÄÚÈÝÖÐÖ÷񻃾¼°AºÍC-RAF¡£¶ÔÁË£¬Ëùν¼¤Ã¸¾ÍÊÇ¿ÉÒÔÒýÆðµ°°×ÖÊÁ×ËữµÄøÀà¡£
3¡¢RAS£¬RAFºÍºóÃæÌáµ½µÄMEF-ERK¹²Í¬¹¹³ÉÁËÒ»Ìõ·Ç³£ÖØÒªµÄÐźÅͨ·£¬Í¨³£³ÆÖ®ÎªRAS-RAF-MEK-ERKÐźÅͨ·£¨RAS-RAF-MEK-ERK signal pathway£© Ò²½ÐË¿ÁÑÔ­¼¤»îµ°°×¼¤Ã¸£¨MAPK£©Í¨Â·£¨mitogen-activated protein kinase (MAPK) cascade£©, ÆäÖÐRAF¼¤Ã¸µÄ»î»¯¾ÍÐèÒªÓëRAS-GTPases£¨GTPø£©Ï໥×÷Óã¬ÕâÒ²¾ÍÊÇÎÄÖÐËùÌá¼°µÄ¡±RAS-dependent BRAF binding to CRAFÒÔ¼°CRAF activation¡°µÄ¹ý³ÌºÍº¬Òå¡£ MEK-ERKÏÔÈ»ÊÇÕû¸öÐźÅͨ·µÄÒ»²¿·Ö£¬Õû¸öÐźÅͨ·¼¤»îºó£¬¾Í»áÓ°ÏìÏÂÓΰлùÒòµÄ±í´ï£¬½ø¶ø¸Ä±äϸ°ûµÄ±íÐÍ¡£
4¡¢a paradigm of BRAF-mediated signaling˵µÄÊÇÓÐBRAF½éµ¼ µÄÐźÅͨ·µÄÒ»¸öģʽ»òÕßÀý×Ó¡£ÒòΪBRAFÔÚÕû¸öͨ·Öд¦ÓÚÉÏÓΣ¬ËùÒÔÀàËÆÒ»¸ö¿ª¹Ø×÷Óã¬ËùÒÔ³ÆÖ®ÎªÓÉBRAF½éµ¼µÄͨ·¡£
5.panRAF inhibitors with anti SRC activity£ºÊǽ²µ½RAFµÄÒÖÖÆ¼Á£¬ÕâÀïµÄÒÖÖÆ¼ÁΪpanRAF£¬panÊÇÖ¸·º»òÕßÈ«µÄÒâ˼£¬¾ÍÊÇ˵ÕâÀàÒÖÖÆ¼Á¿ÉÒÔÒÖÖÆËùÓÐÈýÖÖÀàÐ͵ÄRAF£¬¶ø·ÇÕë¶ÔÆäÖеÄijһÖÖ£»¶øÇÒ¿ÉÒÔÒÖÖÆ£¨¿¹£©SRC»îÐÔ¡£ÕâÀïÓÖÓÐÒ»¸öÃû´ÊSRC£¬ËüÒ²ÊÇÒ»ÖÖ°©»ùÒò£¬Æä²úÎïΪһÖÖÀÒ°±Ëáµ°°×¼¤Ã¸£¨tyrosine-protein kinase£©¡£Í¨¹ýʹÓÃÒÖÖÆ¼Á£¬¿ÉÒÔÓÐЧµØ×èÖ¹¡¢ÇжÏÕûÌõÐźÅͨ·£¬´Ó¶ø¿ÉÒԴﵽijÖÖÄ¿µÄ£¨°üÀ¨ÖÎÁÆ£©¡£

¼øÓÚÄãµÄÇé¿ö£¬ÎÒ¾õµÃÄã¿ÉÒÔÑ¡¶ÁµãÖÐÎĵÄÏà¹Ø×ÛÊö£¬¶ÔÆäÖи÷³ÉÔ±µÄ»ù±¾Çé¿öÓиö´óÖÂÁ˽⣬ÔÙÈ¥¶ÁÔ­ÎÄ¿ÉÄÜ»áºÃЩ¡£·ñÔòÖ»ÄÜÔÆÀïÎíÀïµÄ£¬Ð§¹û²»ºÃ¡£

˳±ã¸½ÉÏÒ»ÕÅÏà¹ØµÄͼ£¬°ïÄãÀí½â¡£
¹ØÓÚRRAFµÄÓ¢ÎÄ·­Ò룬ÓÐЩ¼±£¬Âé·³°ïæ½âÊÍÏ£¬·Ç³£¸Ðл£¡
p_40957.jpg

4Â¥2015-05-10 08:58:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ÒøÉþ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 08¹¤Ñ§ 309·ÖÇóµ÷¼Á +3 Yin DY 2026-04-08 3/150 2026-04-09 16:24 by wp06
[¿¼ÑÐ] Ò»Ö¾Ô¸µç×ӿƼ¼´óѧ085600²ÄÁÏÓ뻯¹¤ 329·ÖÇóµ÷¼Á +13 Naiko 2026-04-04 13/650 2026-04-09 16:04 by may_ÐÂÓî
[¿¼ÑÐ] 289 ·Ö105500ҩѧר˶Çóµ÷¼Á(ÕÒBÇøÑ§Ð£) +5 °×ÔÆ123456789 2026-04-09 6/300 2026-04-09 14:04 by °×ÔÆ123456789
[¿¼ÑÐ] ²ÄÁÏ307·ÖÇó´óÀÐ×éÊÕÁô +17 Hllºú 2026-04-07 17/850 2026-04-09 10:53 by liuhuiying09
[¿¼ÑÐ] 308Çóµ÷¼Á +16 ÌÈÈôÆð·çÁËÄØ 2026-04-05 16/800 2026-04-08 23:03 by Öí»á·É
[¿¼²©] ²ÄÁÏ·½Ïò¿¼²©£¬ÇóÍÆ¼ö +3 ÑÔÓïaaa 2026-04-05 4/200 2026-04-08 22:22 by nxgogo
[¿¼ÑÐ] 285Çóµ÷¼Á +7 ¶ñ·¨´ó¶þµÄÆøÎ¶ß 2026-04-05 10/500 2026-04-08 14:34 by zhq0425
[¿¼ÑÐ] µ÷¼Á +3 µçÆø300Çóµ÷¼Á²» 2026-04-08 6/300 2026-04-08 09:39 by µçÆø300Çóµ÷¼Á²»
[¿¼ÑÐ] 259Çóµ÷¼Á +5 ¾Í°®³ÔÍÁ¶¹Ñ½Ñ½ 2026-04-07 5/250 2026-04-07 22:40 by JourneyLucky
[¿¼ÑÐ] 316Çóµ÷¼Á +4 15318418673 2026-04-07 4/200 2026-04-07 22:12 by hemengdong
[¿¼ÑÐ] 363Çóµ÷¼Á +9 zh096 2026-04-04 9/450 2026-04-07 21:51 by 418490947
[¿¼ÑÐ] 269µç×ÓÐÅÏ¢Çóµ÷¼Á£¬¿Éתרҵ +5 ¶À×Ãwl 2026-04-06 5/250 2026-04-06 17:23 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] 319Çóµ÷¼Á +3 handrui 2026-04-05 3/150 2026-04-06 09:33 by jp9609
[¿¼ÑÐ] ²ÄÁÏר˶283Çóµ÷¼Á +17 ÊÔÊÔ¿´ß 2026-04-04 18/900 2026-04-06 09:24 by 286640313
[¿¼ÑÐ] ²ÄÁÏר˶(0856) 339·ÖÇóµ÷¼Á +10 ¹þ¹þ¹þ¶ì¹þ¹þ¹þ 2026-04-04 10/500 2026-04-05 18:51 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 0854Çóµ÷¼Á +4 assdll 2026-04-04 4/200 2026-04-05 09:44 by zhq0425
[¿¼ÑÐ] µ÷¼ÁÇóÖú +10 Ïë»»ÊÖ»ú²»Ïë½âÊ 2026-04-02 13/650 2026-04-05 09:41 by sam3303
[¿¼ÑÐ] µ÷¼Á +8 ÐܶþÏëÉϰ¶ 2026-04-04 8/400 2026-04-05 05:27 by houyaoxu
[¿¼ÑÐ] 293Çóµ÷¼Á +5 ĩδmm 2026-04-02 6/300 2026-04-03 15:20 by Íõ±£½Ü33
[¿¼ÑÐ] ÍÁľˮÀû328·ÖÇóµ÷¼Á +6 ¼²·çÖª¾¢²Ý666 2026-04-02 6/300 2026-04-03 11:38 by znian
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û